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Neuropathic pain is a chronic symptom of multiple sclerosis (MS) and affects nearly half of
all MS sufferers. A key instigator of this pain is the pro-inflammatory response in MS. We
investigated the behavioral effects of immunization with a mutant peptide of myelin basic
protein (MBP), termed altered peptide ligand (APL), known to initiate immune deviation
from a pro-inflammatory state to an anti-inflammatory response in experimental autoim-
mune encephalomyelitis (EAE), an animal model of MS. Male and female Lewis rats were
injected with vehicle control or with varying doses of 50 or 100µg guinea pig MBP in com-
bination with or without APL. APL-treated animals established significantly lower disease
severity compared to encephalitogenic MBP-treated animals. Animals with EAE devel-
oped mechanical, but not thermal pain hypersensitivity. Mechanical pain sensitivities were
either improved or normalized during periods of clinical disease in male and female APL-
treated animals as compared to the encephalitogenic group. No significant changes to
thermal latency were observed upon co-immunization with APL. Together these data indi-
cate that APL ameliorates disease states and selectively mediates an analgesic effect on
EAE animals.
Keywords: experimental autoimmune encephalomyelitis, altered peptide ligand, multiple sclerosis, mechanical
allodynia, thermal hyperalgesia, nociception
INTRODUCTION
Multiple sclerosis (MS) is a chronic, T cell-mediated autoimmune
neurological disease of the central nervous system (CNS) (1, 2),
characterized by the production of acute multifocal CNS lesions
with concurrent perivenular inflammation, demyelination, neu-
ronal degeneration, and gliosis in gray and white matter (3, 4).
While the cause of the disease is not known, pro-inflammatory
CD4+ T cells, CD8+ T cells, B cells, macrophages, and natural
killer cells have been implicated in disease onset and progression
(4, 5). In addition, the dichotomous actions of pro- and anti-
inflammatory cytokines are known to play a major role in disease
exacerbation and amelioration respectively (6).
Neuropathic pain is a key clinical symptom in MS, with sig-
nificant interference of quality of life (7–10). It results from dam-
age to the nervous system (11), and presents in various forms
such as ongoing extremity pain, paroxysmal neuropathic pain
(e.g., trigeminal neuralgia, Lhermitte’s phenomenon), hyperal-
gesia (increased sensitivity to pain), and allodynia (pain pro-
duced by innocuous stimuli) (8, 12–14). While the mechanisms
underlying MS-related neuropathic pain are not fully understood,
lesions of CNS areas associated with pain, activation of T lym-
phocytes, and pro-inflammatory responses have been shown to
contribute to the development and maintenance of neuropathic
pain (15–17).
Experimental autoimmune encephalomyelitis (EAE) is a well-
established and ubiquitous animal model that exhibits close
clinical and histopathological similarities to various forms of MS
(18). Following induction in susceptible animals by injections
with a self-antigenic myelin-derived peptide, such as myelin basic
protein (MBP), priming of antigen-specific lymphocytes occurs
in the periphery. These cells subsequently migrate to the CNS,
where they produce inflammatory mediators and cytokines that
damage the myelin and axons and activate resident microglia
to attract more inflammatory cells, resulting in inflammatory
demyelination and neurodegeneration (19). Recent studies in
rodents have demonstrated that animals with EAE develop
neuropathic pain behaviors, including tactile and cold allody-
nia, and mechanical and thermal hyperalgesia (20–22). These
symptoms have been observed before, during, and after neu-
rological impairment, depending on the strain and the model
used (17).
Epitopes derived from autoantigens involved in the autoim-
mune pathogenesis can be modified to modulate their immuno-
logical properties, and are called altered peptide ligands (APLs).
APLs are similar to the immunogenic peptide, but with one
or more amino acid substitutions in the essential contact posi-
tions, with the T cell receptor interfering with the T cell acti-
vation. Thus, APLs have the capacity to affect T cell receptor-
mediated effector functions (23, 24), such as conferring an anergic
effect on specific T cell subsets, or rendering them irrespon-
sive to specific antigens despite presence of functioning anti-
gen presenting cells (25). Different signaling mechanisms can
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also be activated to initiate a functional change in the T cell
phenotype (24, 26), thereby altering cytokine production and
downstream mechanisms (27) to selectively down-regulate pro-
inflammatory TH1 cells (but not TH2 cells), as well as selectively
inducing T lymphocytes that produce TH2 and TH0 cytokines
(28). The ability for APLs to divert immune responses to a
TH2 profile has been validated in several studies (26, 29–31).
Importantly, TH2 cellular response has been shown to amelio-
rate EAE mediated by encephalitogenic TH1 population (28, 29,
31–33), as well as ameliorate pain states (15, 16, 34). As TH1
cells are widely believed to mediate pro-inflammatory effects,
releasing a distinct set of cytokines that exacerbate pain states
(35–37), their downregulation could similarly ameliorate clinical
symptoms.
Our study builds upon the concept of immune deviation
through APLs. While the effectiveness of myelin-derived APL in
preventing EAE is well documented,we hypothesize that APL inoc-
ulation through immune deviation mediates an analgesic effect
in this animal model of MS. Indeed, our results are the first to
demonstrate that MBP-derived APL helps to restore EAE-affected
mechanical pain thresholds.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
Male (n= 36) and female (n= 18) 6- to 8-week-old Lewis rats
(Animal Resource Centre, Perth, WA, Australia) were used. Ani-
mals were housed with food and water ad libitum under 12-h
light cycle, with constant humidity and temperature. Animals that
developed mobility impairment were provided with soft jelly foods
and easier access to water. Cage beddings changed twice a week,
and animals were inspected daily for well-being. All animal exper-
iments were approved by the Animal Care and Ethics Committee
of the University of New South Wales, Sydney, NSW, Australia.
PEPTIDES
Encephalitogenic guinea pig MBP (gp-MBP) is known to induce
acute TH1-associated EAE in Lewis rats (38). Doses of 50 or 100µg
gp-MBP (Sigma-Aldrich, NSW, Australia) were used to induce
EAE. Previous studies using site-directed mutagenesis to compare
different mutant peptides have shown that the peptide MBP87–99,
with double Ala mutations at positions 91,96-[A91,A96]MBP87–99,
alters immune responses leading to decrease in EAE severity (39–
41). Our study was designed to assess the effects of this mutant
peptide on sensory disturbances in EAE animals. In addition,cyclic
peptides have been shown to be more stable in vivo, and have sim-
ilar immunological activity to their linear counterparts (42). For
increased stability, the [A91,A96]MBP87–99 peptide was cyclized
from head to tail resulting in cyclo-(87–99)[A91,A96]MBP87–99.
The cyclic double mutant cyclo-(87–99)[A91,A96]MBP87–99 pep-
tide at a dose of 250µg was used as the APL to inhibit EAE. Peptides
were synthesized and purchased from Mimotopes Australia with
purity greater than 95%.
EAE INDUCTION
To induce EAE, rats were anesthetized (day 0) with 3% Isoflu-
rane in oxygen, and inoculated at the base of the tail with a
single subcutaneous injection of 200µL inoculum. The control
group was injected with an inoculum containing sterile saline
(0.9% NaCl) emulsified with an equal volume of incomplete Fre-
und’s adjuvant (IFA; Difco Laboratories, Detroit, MI, USA) sup-
plemented with desiccated 1 mg/mL Mycobacterium tuberculosis
(strain H37RA, Difco Laboratories). The IFA with Mycobacterium
tuberculosis is defined as CFA. A second group was injected with
either 50 or 100µg gp-MBP emulsified in CFA (deemed the MBP
group), while a third group was injected with equal dose of gp-
MBP, but an additional 250µg cyclo-(87–99)[A91,A96]MBP87–99
(APL group).
CLINICAL ASSESSMENT
Following disease induction, animals were assessed daily for signs
of disease for up to 35 days, graded using the following scale:
Grade 0, normal rat; Grade 1, flaccid tail; Grade 2, weak hind
limbs with ataxia; Grade 3, hind limb paralysis; Grade 4, paraple-
gia with forelimb paralysis; Grade 5, moribund. Weight changes
were also recorded.
PAIN ASSESSMENT
Behavioral tests were conducted three times a week prior to and
up to 4 weeks following EAE induction.
Prior to testing, animals were acclimatized in a clear Perspex
20 cm× 20 cm box standing 20 cm above the bench for 15 min
until they were in a non-agitated state. Thermal hyperalgesia was
assessed by exposing the plantar hind paw of the animal to radi-
ant heat through the transparent floor of the Perspex box, using
a plantar analgesia meter (Ugo Basile, Varese, Italy). A cut-off of
20 s was applied to prevent tissue damage.
Mechanical allodynia was then assessed subsequent to 30-min
break, by an electronic von Frey anesthesiometer (Ugo Basile). The
animal, placed upon an elevated wire mesh surrounded by a Per-
spex box, was exposed to increasing mechanical pressure to the
plantar hind paw through a metal filament.
Withdrawal latency and threshold was measured automatically
from the initiation of heat or mechanical stimulus to withdrawal
of the paw, defined as sudden jerk of paw away from stimulus. This
was repeated three times in both left and right hind paw separated
by 2–5 min between each stimulus. Mean results for each animal
was calculated.
DATA ANALYSIS
In mechanical and thermal tests, raw scores for left and right
hind paws were combined and averaged for each time-point.
Time periods were classified as pre-disease, disease peak, and
recovery, defined as time-points prior to development of clin-
ical signs, presence of clinical signs, and resolution of clini-
cal signs respectively. Disease peak periods are shaded gray in
Figures 1–3.
For measurements of pain behaviors, data were analyzed with
repeated measures two-way ANOVA with Bonferroni’s post-test,
and for EAE clinical scores data were analyzed with a non-
parametric Mann–Whitney test as appropriate, using GraphPad
Prism v5.04 (GraphPad Software, Inc., CA, USA). Significance was
set at p< 0.05. All data are presented as mean± SEM.
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FIGURE 1 | Pain hypersensitivity (top set) and clinical score (bottom
set) in male Lewis rats injected with 100µg gp-MBP on day 0. Top
series represent response to stimuli, while bottom series represent clinical
score. EAE clinical scores of rats immunized with MBP were significantly
greater than those of APL-treated or CFA-immunized (control) animals
during period of established disease. (A) MBP-treated animals
demonstrated a decrease in paw withdrawal thresholds to mechanical
stimulus, while APL-treated animals had significantly elevated mechanical
pain thresholds, in particular during disease recovery. (B) No significant
difference was observed in paw withdrawal latency to thermal stimuli
between APL-treated and MBP-treated animals. (n=6 per group;
****p<0.0001, MBP compared to control; ◦p<0.05, ◦◦◦p<0.005, APL
compared to MBP; two-way ANOVA with Bonferroni’s post-tests for upper
panel, Mann–Whitney test for lower panel). Gray region indicates periods
of established disease. Dotted line represents mean baseline values. Data
expressed as mean±SEM.
FIGURE 2 | Changes in mechanical sensitivity (top set) in male and
female Lewis rats inoculated with 50µg gp-MBP on day 0 compared to
clinical scores (bottom set). In both males and females, EAE clinical scores
of rats immunized with MBP were significantly greater than those of
APL-treated or CFA-immunized (control) animals during period of established
disease. (A) In males, APL conferred significant increase in mechanical
threshold compared to MBP-treated rats on day 11, 14, 16. (B) In females,
MBP animals generally exhibited lower pain thresholds, while APL animals
maintained thresholds similar to control. (n=6 per group; *p<0.05,
****p<0.0001, MBP compared to control; ◦p<0.05, ◦◦p<0.01, APL
compared to MBP; two-way ANOVA with Bonferroni’s post-tests for upper
panel, Mann–Whitney test for lower panel). Gray region indicates periods of
established disease. Dotted line represents mean baseline values. Data
expressed as mean±SEM.
RESULTS
EFFECTS OF CO-IMMUNIZATION WITH APL,
CYCLO-(87–99)[A91,A96]MBP87–99, IN MALE LEWIS RATS INJECTED WITH
100µg gp-MBP
We first studied the effects of APL vaccination on EAE clin-
ical disease course and changes to mechanical threshold and
thermal latency for pain in 18 male Lewis rats immunized with
100µg gp-MBP. Three study groups were used, (i) animals
injected with CFA only (vehicle control), (ii) animals injected
with CFA+ 100µg gp-MBP (MBP group) and, (iii) animals
co-immunized with CFA+ 100µg gp-MBP+ 250µg cyclo-(87–
99)[A91,A96]MBP87–99 (APL group).
Treatment with APL significantly reduced disease severity in male
animals with EAE
Both MBP-treated and APL-treated animal groups demonstrated
characteristic clinical deficits beginning on day 8 (Figures 1A,B).
Vehicle-treated animals displayed minimal clinical deficits. Onset
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FIGURE 3 | Changes in thermal sensitivity (top) in male and female
Lewis rats inoculated with 50µg gp-MBP on day 0 compared to clinical
scores (bottom). EAE clinical disease is as in Figure 2. (A) In males, no
significant difference was observed between control, MBP-treated, and
APL-treated animal groups. (B) In females, MBP evoked a transient increase in
latency on day 14, with no other significant difference observed at any other
time-points. (n=6 rats per group, ***p<0.001, MBP compared to control;
two-way ANOVA with Bonferroni’s post-tests; upper panel). Gray region
indicates periods of established disease. Dotted line represents mean
baseline values. Data expressed as mean±SEM.
was characterized by weakness of tail, followed by ascending motor
deficits.
Disease severity in MBP-treated animals peaked later on day
17 with a mean maximal score of 1.7± 0.5 (n= 6), while the APL
cohort peaked earlier on day 13 with 82% comparative reduction
in average maximal severity (peak mean score 0.9± 0.08). APL
animals recovered significantly earlier compared to MBP animals
(22.5 days for MBP and 18.8 days for APL, Mann–Whitney test,
p< 0.01).
Overall, MBP animals demonstrated significantly greater EAE
clinical scores than vehicle-treated animals when clinical signs
were present between day 8 and 23 (p< 0.0001, Mann–Whitney
test). Compared to MBP, the APL group showed a significant
reduction in clinical scores during the same period (p< 0.005,
Mann–Whitney test).
Treatment with APL significantly increased thresholds to
mechanical stimuli following disease resolution
Prior to disease onset on day 8 (Figure 1A) and during disease
establishment (day 8–23, gray region), no significant differences in
paw withdrawal thresholds to mechanical stimuli were observed
between CFA-injected control, MBP-, and APL-treated animals
(p> 0.05, two-way ANOVA). Following resolution of clinical dis-
ease, MBP animals developed reduced mechanical thresholds,
while APL animals exhibited significantly elevated thresholds
of as much as 6.90 g compared to MBP animals on days 24
and 26 (p< 0.05, two-way ANOVA). Although not statistically
significant, compared to control animals, MBP animals gener-
ally possessed lower thresholds to mechanical pain, particularly
after disease peak, whereas APL animals demonstrated elevated
thresholds.
Interestingly, a sharp increase in withdrawal threshold was
observed in MBP animals on day 16, corresponding closely to
the rats’ maximal disease severity (score 1.7). While hindlimb
paralysis has the potential to confound results, results for
all three groups became relatively stabilized following animal
recovery.
No significant changes to thermal latency were observed in animals
co-immunized with APL
In addition to evaluating alterations of mechanical pain thresh-
olds, we examined changes to paw withdrawal latency in
response to thermal stimulation (Figure 1B). Interestingly, no
difference was observed between any of the cohorts prior to,
during, and following disease establishment (p> 0.05, two-
way ANOVA). We conclude that male animals with EAE
do not develop thermal pain hypersensitivity and that APL
does not confer any significant effects on latency to thermal
stimuli.
EFFECTS OF CO-IMMUNIZATION WITH APL,
CYCLO-(87–99)[A91,A96]MBP87–99, IN MALE AND FEMALE RATS
INJECTED WITH 50µg gp-MBP
To reduce confounding effects of severe hind limb paralysis on
the ability of animals to withdraw their paw from the stimu-
lus, we halved the MBP dose to 50µg in order to minimize
physical paralysis. Since previous studies have demonstrated dif-
ferences between sexes in EAE severity and nociception, we tested
both male and female rats for clinical EAE and pain sensitiv-
ity. Here we used 18 male and 18 female Lewis rats immunized
with CFA only (control), CFA+ 50µg gp-MBP (MBP group), and
CFA+ 50µg gp-MBP+ 250µg cyclo-(87–99)[A91,A96]MBP87–99
(APL group).
Treatment with APL reduced disease severity in both male and
female animals with EAE
Disease onset in male MBP animals occurred around day 10 and
in female MBP animals around day 8 (Figures 2A,B). Addition-
ally, the disease course of male animals peaked later (day 16) than
female animals (day 14). Recovery for both sexes occurred on
day 23.
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Significant differences between the disease course of male
and female MBP animals were observed. Female animals devel-
oped clinical signs that were on average 151% more severe than
male animals (result reported as percentage of difference com-
pared to male animals, p< 0.05; Mann–Whitney test). For exam-
ple, three female MBP animals developed scores of 3 (complete
paralysis of tail and hind limbs), whilst the male MBP cohorts
only managed to develop maximal scores of 1.5 (paralysis of
tail only).
Separately, there existed a significant difference in clinical scores
between CFA and MBP, and MBP and APL groups in both sexes
when clinical signs were present (day 10–22 for males, day 8–22 for
females) (Figures 2A,B). Both male and female MBP animals dis-
played significantly greater EAE clinical scores than CFA animals
(p< 0.0001 in both, Mann–Whitney test). Both male and female
APL animals showed a significant reduction in EAE severity as
compared to MBP animals (p< 0.05, Mann–Whitney test) dur-
ing established disease. These results highlight APL’s ameliorative
effect on disease status in both males and females.
Treatment with APL significantly ameliorated mechanical pain
sensitivities in both male and female animals during established
disease
In male animals, APL normalized changes in EAE-induced
mechanical pain thresholds only during periods when clini-
cal signs were present. No significant difference was observed
between the three cohorts prior to and following disease estab-
lishment, except a small reduction in threshold in APL-treated
animals compared to MBP animals on day 2 (p< 0.05, two-way
ANOVA). When clinical signs of disease were evident on day 10–22
(Figure 2A, gray region), MBP animals exhibited lower mechan-
ical pain thresholds compared to control, while no significant
differences were observed between APL and control (p> 0.05,
two-way ANOVA). Furthermore, on day 11, 14, and 16, ani-
mals co-immunized with APL demonstrated threshold increase
of at least 2.6 g against MBP animals (p< 0.05, two-way ANOVA)
and their paw withdrawal threshold to mechanical stimulus was
similar to control animals. This validates the ability for APL
to ameliorate changes to mechanical pain thresholds in animals
with EAE.
In female animals, APL’s ameliorative effects were similarly evi-
dent mostly during established disease (Figure 2B, gray region).
Prior to disease onset, no significant differences in mechanical
threshold were observed between the cohorts (p> 0.05, two-
way ANOVA). MBP animals developed a sharp decrease in
mechanical threshold starting on day 9 following disease induc-
tion, followed by a steady increase, potentially associated with
the escalating disease severity. The threshold started to reduce
again on day 18, following amelioration of paralytic signs. When
clinical signs were present between day 8 and 22, MBP ani-
mals exhibited a general reduction in threshold, particularly
noticeable on day 11 and 21 (p< 0.05, two-way ANOVA). Dur-
ing the same period, APL animals displayed similar thresh-
olds to control, which were significantly elevated against MBP
on day 18 (p< 0.05, two-way ANOVA). Again, this indicates
the normalization of mechanical thresholds in APL animals
with EAE.
No significant changes to thermal latency were observed in
APL-treated animals
In male animals, no significant latency variations to thermal stim-
uli were observed between any time-points during the course of
the experiment (Figure 3A; p> 0.05, two-way ANOVA), similar
to the results from male animals inoculated with twice the MBP
dosage (Figure 1).
In female animals, immunization with only MBP was able to
increase thermal latency by 4.8 s on day 14 compared to control
(Figure 3B; p< 0.001, two-way ANOVA). However, it should be
noted that this transient increase occurred concurrent with disease
peak, therefore it is possible that animal paralysis has confounded
results. At the same time-point, APL animals, which exhibited less
severe paralysis, displayed no significant difference compared to
control. No other changes were observed during the course of the
experiment.
DISCUSSION
Over the last two decades, numerous studies in rodents
have demonstrated that several non-encephalitogenic myelin-
derived APLs confer protection from the development of
EAE, and even reverse established paralytic disease (26,
28, 29). These APLs were shown to induce T cells that
are cross-reactive with the native myelin peptide, but
modify the immune response and prevent autoimmune
encephalomyelitis. Our results here have shown that active
immunization with the APL cyclo-(87–99)[A91,A96]MBP87–99
in an animal model of EAE, not only mitigated the dis-
ease course, but also improved symptoms of mechanical pain
hypersensitivity.
We demonstrated that in both male and female Lewis
rats, co-immunization with gp-MBP and APL cyclo-(87–
99)[A91,A96]MBP87–99 has significantly reduced EAE disease
severity and shortened the disease course as compared to gp-
MBP alone. These results are in line with previous studies (26,
28, 31, 43, 44). We also demonstrated that EAE severity is
dependent upon MBP dosage and gender. It is well known that
many autoimmune diseases, including MS, are more predisposed
toward females than males (45). Our study determined female
animals were significantly more affected by equal dosages of
MBP, with clinical scores of female rats more than twice that
of male animals. A dose of 100µg MBP was able to elicit mean
peak disease score of 1.7 in male Lewis rats, while 50µg MBP
was only able to generate considerably lower mean peak score
of 0.7. Female rats were more affected by MBP immunization,
with only 50µg MBP producing a mean peak score of 1.75,
comparable to doubling the dosage in male animals. Indeed, it
has been shown that immunization with gp-MBP induced dis-
ease in all female mice, but only in half of male animals (46).
Variations in encephalitogenic peptides and animal strains sim-
ilarly indicated that female animals were more severely affected
(20, 47, 48).
Chronic neuropathic pain arises subsequent to lesion or dis-
ease of the somatosensory nervous system (11). Recent studies
have shown that T lymphocytes and pro-inflammatory cytokines
play a significant role in the development and maintenance of
neuropathic pain (34, 49). For example, injection of a TH1 cell
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population producing pro-inflammatory cytokines increased the
level of neuropathic pain, whereas injection of a TH2 cell pop-
ulation producing anti-inflammatory cytokines attenuated pain
sensitivity in nerve-injured rats (15). As chronic neuropathic pain
affects the majority of MS patients (10, 17), it is believed that mod-
ulation of pro-inflammatory T cells and their associated cytokine
response will mitigate such symptoms.
Our results show that concurrent inoculation with APL, in
addition to disease-causing MBP, normalizes disturbances to
mechanical pain threshold, particularly during established dis-
ease, although it had no significant effect on thermal latency to
pain. Consistent with previous studies (21, 22, 50, 51), we found
that animals with EAE display mechanical allodynia during the
course of the disease. In addition, we observed normalization or
increase in pain threshold to mechanical stimuli during periods of
clinical disease in animals co-immunized with APL. While there
existed some association between changes to mechanical thresh-
old and disease severity, particularly in MBP animals, threshold
trends persisted even following resolution of clinical paralysis.
Overall, treatment with APL displayed a tendency to normalize
pain thresholds, and hinder the development of mechanical pain
hypersensitivity.
In MS, neuro-inflammatory lesions in the CNS produce signif-
icant somatosensory deficit, particularly in temperature discrim-
ination, such as paradoxical heat sensations and altered heat/cold
thresholds (52–54). In our experiments with male and female
MBP animals, no differences in latency to thermal stimuli were
observed, except in transience. Similarly, Olechowski et al. (21)
reported no change in sensitivity to noxious heat, albeit using a
different encephalitogenic peptide and animal model (21). In con-
trast, thermal hyperalgesia was observed in the tail and forepaws
of male and female SJL mice, using a proteolipid protein from the
myelin sheath as immunogenic source. These conflicting results
underscore the high variability existent between differing animal
models and encephalitogenic peptides. Consequently, we were not
able to show any differences caused by APL co-immunization. It
should be noted, however, that paralysis of the hind paws could
have potentially confounded results, a concern shared by oth-
ers (20, 21). Additional experimental setups that diminish the
impact of paralysis on nociceptive testing, such as measuring
vocalization response (55) or spontaneous pain (56) in animals,
are encouraged.
As pain has only recently been recognized as a key functional
disability of MS, a clear understanding of its pathogenesis is still
absent. Several theories exist to explain this pain, including dam-
age to somatosensory nerves (57), lesions in the CNS and spinal
cord inflammation (17). However, a key factor is the dichotomous
role of pro- and anti-inflammatory responses. Indeed, a recent
study has shown that animals with EAE did not have altered
expression of sensory neuropeptides, but possessed an influx of
CD3+ T cells and increased astrocyte and microglia/macrophage
reactivity in the superficial dorsal horn of the spinal cord, an
area associated with pain processing (21). Additionally, a sig-
nificant increase in the level of tumor necrosis factor (TNF)
expression, a key pro-inflammatory cytokine, in the dorsal root
ganglia of EAE animals was found at disease peak (58). Gene
therapy with anti-inflammatory interleukin (IL)-10 resulted in
prevention of the onset of allodynia in animals with EAE (50). Col-
lectively, these findings suggest that pro-inflammation and gliosis
are key mediators in the neuropathic pain behaviors associated
with EAE.
The mechanisms underlying the analgesic effect of APL immu-
nization in EAE-induced mechanical pain hypersensitivity are
not known, but may include: reduced production of interferon-
γ and TNF, pro-inflammatory cytokines that are critical in the
pathogenesis of EAE (29); up-regulation of anti-inflammatory
cytokines IL-4, IL-10, IL-13 and transforming growth factor-β
(32); diverting immune responses from TH1 to TH2 (33); and
mediating bystander suppression by the generation of regulatory
T cells (59), which have been shown to suppress pain hypersen-
sitivity in nerve-injured animals (60). In addition, APL immu-
nization in EAE animals may have affected other pain mediators
such as bradykinin, eicosanoids (prostaglandins and leukotrienes),
adenosine-5′-triphosphate (ATP), histamine, chemokines (e.g.,
chemotactic cytokine ligand 2, fractalkine), neurotrophins (e.g.,
nerve growth factor, brain-derived neurotrophic factor), and reac-
tive oxygen species to reduce mechanical pain hypersensitivity
(16). Future studies will have to investigate the impact of APL
treatment on immune modulation and inflammatory mediators
associated with EAE pain.
While recent studies have mostly focused on individual single
T cell clones in animal models (61), clinical trials have underlined
the complexity of APLs. Despite APL’s effective suppression and
reversal of EAE in rodents (29, 30), human trials reported conflict-
ing results. In one phase II trial using [A91]MBP83–99, a decrease in
the size of new MS lesions on MRI scans was observed in human
subjects, but the trial was halted due to hypersensitivity reactions
in 9% of patients (62). Crucially, there was no increase in disease
exacerbation, although this did present in a similar phase II clinical
trial (63). Thus, further clinical use of APLs is considered ques-
tionable. However, this avenue of research holds great promise,
as the immune changes instigated by the APLs could induce 2–
4.5 years of TH2-directed deviation in humans (64). Experimental
trends show that clinical benefit and allergy mitigation is related
to the correct dose of APL and route of administration, both of
which necessitate further investigation (65).
Although our results highlight the restorative effect of APL on
mechanical pain thresholds, further work is required to elucidate
the mechanisms behind such changes. Challenges also remain in
translating results from animal experiments into human thera-
pies. Dosages need to be accurately titrated to maximize disease
reduction while minimizing side effects, particularly TH2-induced
hypersensitivity reactions. However, should this avenue of research
yield promising results, it will herald a new field of immune devia-
tion as a therapeutic option to neuropathic pain in MS and similar
diseases.
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